Jane Yardley

770 total citations
33 papers, 525 citations indexed

About

Jane Yardley is a scholar working on Experimental and Cognitive Psychology, Cognitive Neuroscience and Endocrine and Autonomic Systems. According to data from OpenAlex, Jane Yardley has authored 33 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Experimental and Cognitive Psychology, 20 papers in Cognitive Neuroscience and 5 papers in Endocrine and Autonomic Systems. Recurrent topics in Jane Yardley's work include Sleep and related disorders (24 papers), Sleep and Wakefulness Research (20 papers) and Circadian rhythm and melatonin (5 papers). Jane Yardley is often cited by papers focused on Sleep and related disorders (24 papers), Sleep and Wakefulness Research (20 papers) and Circadian rhythm and melatonin (5 papers). Jane Yardley collaborates with scholars based in United States, United Kingdom and Japan. Jane Yardley's co-authors include Margaret Moline, Kate Pinner, Carlos Perdomo, Elimor Brand‐Schieber, Timothy Hsu, Heng Zou, Andrew Satlin, Martin R. Farlow, Naoki Kubota and Yuichi Inoue and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and SLEEP.

In The Last Decade

Jane Yardley

30 papers receiving 509 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Yardley United States 9 246 226 155 146 117 33 525
Eric Legangneux Switzerland 14 163 0.7× 118 0.5× 86 0.6× 71 0.5× 123 1.1× 29 581
P. Danjou France 11 133 0.5× 118 0.5× 60 0.4× 21 0.1× 121 1.0× 25 404
B Ganaraja India 11 96 0.4× 34 0.2× 54 0.3× 45 0.3× 43 0.4× 36 515
Liuqing Huang China 13 164 0.7× 122 0.5× 40 0.3× 116 0.8× 36 0.3× 18 357
Martin Schnelle Germany 7 112 0.5× 22 0.1× 611 3.9× 44 0.3× 67 0.6× 8 818
Alfred L van Steveninck Netherlands 8 194 0.8× 82 0.4× 122 0.8× 36 0.2× 108 0.9× 11 586
Rika Aizawa Japan 11 237 1.0× 200 0.9× 33 0.2× 174 1.2× 32 0.3× 13 569
Mark Leibowitz United States 11 37 0.2× 24 0.1× 185 1.2× 18 0.1× 108 0.9× 16 522
Brett A. English United States 12 100 0.4× 26 0.1× 120 0.8× 8 0.1× 72 0.6× 19 456
Zahed Subhan United Kingdom 10 153 0.6× 109 0.5× 56 0.4× 13 0.1× 76 0.6× 12 382

Countries citing papers authored by Jane Yardley

Since Specialization
Citations

This map shows the geographic impact of Jane Yardley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Yardley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Yardley more than expected).

Fields of papers citing papers by Jane Yardley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Yardley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Yardley. The network helps show where Jane Yardley may publish in the future.

Co-authorship network of co-authors of Jane Yardley

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Yardley. A scholar is included among the top collaborators of Jane Yardley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Yardley. Jane Yardley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Drake, Christopher L., Jane Yardley, Kate Pinner, Margaret Moline, & Manoj Malhotra. (2025). Perception of Lemborexant Effectiveness as Assessed by the Patient Global Impression–Insomnia Questionnaire. Nature and Science of Sleep. Volume 17. 557–570. 1 indexed citations
2.
Côté, Kimberly A., et al.. (2025). Effect of Lemborexant on Daytime Functioning in Adults With Insomnia. The Primary Care Companion For CNS Disorders. 27(1). 1 indexed citations
3.
Krystal, Andrew D., Pierre Blier, Larry Culpepper, et al.. (2024). Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms. Neuropsychopharmacology Reports. 45(1). e12509–e12509. 2 indexed citations
4.
5.
Yardley, Jane, Yuichi Inoue, Kate Pinner, et al.. (2023). Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study. Sleep Medicine. 110. 111–119. 2 indexed citations
6.
Dash, Amitabh, Kate Pinner, Yuichi Inoue, et al.. (2022). Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder. SHILAP Revista de lepidopterología. 4. 100044–100044. 4 indexed citations
7.
Roth, Thomas, Russell Rosenberg, Charles M. Morin, et al.. (2022). Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder. Sleep Medicine. 90. 249–257. 14 indexed citations
8.
Rosenberg, Russell, Margaret Moline, Jane Yardley, et al.. (2022). Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder. Postgraduate Medicine. 134(3). 316–325. 9 indexed citations
9.
Inoue, Yuichi, Takeshi Watanabe, Kohei Ishikawa, et al.. (2021). Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study. Journal of Clinical Sleep Medicine. 17(5). 1067–1074. 6 indexed citations
10.
Yardley, Jane, Mikko Kärppä, Yuichi Inoue, et al.. (2021). Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Medicine. 80. 333–342. 53 indexed citations
11.
12.
Moline, Margaret, Jane Yardley, Kate Pinner, et al.. (2020). Efficacy and Safety of Lemborexant in Elderly Subjects with Insomnia Disorder: Pooled Analyses from SUNRISE-1 and SUNRISE-2 (1860). Neurology. 94(15_supplement). 2 indexed citations
13.
Drake, Chad E., et al.. (2019). Impact of lemborexant treatment on the patient global impression - insomnia scale. Sleep Medicine. 64. S96–S97. 1 indexed citations
14.
Yardley, Jane, Mikko Kärppä, Yuichi Inoue, et al.. (2019). Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: 12-month results from sunrise-2. Sleep Medicine. 64. S263–S264. 3 indexed citations
15.
Roth, Tom, Russell Rosenberg, Patricia Murphy, et al.. (2019). 0371 Lemborexant Treatment for Insomnia in Phase 3: Impact on Disease Severity. SLEEP. 42(Supplement_1). A151–A151. 2 indexed citations
16.
Kärppä, Mikko, Margaret Moline, Jane Yardley, et al.. (2019). 0367 Lemborexant Treatment for Insomnia: 6-month Safety. SLEEP. 42(Supplement_1). A149–A150. 2 indexed citations
17.
Tariot, Pierre N., Steven Salloway, Jane Yardley, Joan Mackell, & Margaret Moline. (2012). Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease. BMC Research Notes. 5(1). 283–283. 18 indexed citations
18.
Farlow, Martin R., Felix Veloso, Margaret Moline, et al.. (2011). Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology. 11(1). 57–57. 65 indexed citations
19.
Farlow, Martin R., Stephen Salloway, Pierre N. Tariot, et al.. (2010). Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clinical Therapeutics. 32(7). 1234–1251. 149 indexed citations
20.
Yardley, Jane, M P Wailoo, & Mehmet Harman. (1984). Postperinatal mortality among infants discharged from special care units.. BMJ. 288(6414). 366–367. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eric Legangneux Breakdown of academic impact, for papers by P. Danjou Breakdown of academic impact, for papers by B Ganaraja Breakdown of academic impact, for papers by Liuqing Huang Breakdown of academic impact, for papers by Martin Schnelle Breakdown of academic impact, for papers by Alfred L van Steveninck Breakdown of academic impact, for papers by Rika Aizawa Breakdown of academic impact, for papers by Mark Leibowitz Breakdown of academic impact, for papers by Brett A. English Breakdown of academic impact, for papers by Zahed Subhan
Rankless by CCL
2026